A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors

Trial Profile

A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Alpelisib (Primary) ; Infigratinib (Primary)
  • Indications Advanced breast cancer; Male breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 09 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 22 Sep 2016 This trial has been completed in Netherlands, according to European Clinical Trials Database.
    • 19 Sep 2016 This trial was completed in Belgium, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top